Chinese officials have accused the drugmaker of orchestrating a massive bribery and corruption scheme, putting it at risk of fines and legal action, major damage to its reputation, and loss of business in a key growth market.
Subscribe
‘Enforcement 40’ for 2020
Our Sponsors
Join Us On LinkedIn
Join the Securities Litigation and Enforcement Group on LinkedIn